

ReviewForm3

Journal Name:	InternationalResearchJournalof Oncology
ManuscriptNumber:	Ms_IRJO_123000
TitleoftheManuscript:	BreakingBarriers inNonSmallCellLungCancer Treatment: Ceritinib’sRoleinAdvancingTargetedTherapy
TypeoftheArticle	

PART 1: Review Comments

Compulsory REVISION comments	Reviewer’scomment	Author’sFeedback (Please correctthemanuscriptand highlight thatpart in themanuscript. Itismandatorythatauthorsshould writehis/herfeedback here)
Please write a few sentences regarding the importance of this manuscript for the scientific community. Why do you like (or dislike) this manuscript? A minimum of 3-4 sentences may be required for this part.	This is a well-written narrative on Ceritinib, an ALK inhibitor. I appreciate your time and efforts in narrating. This drug is preferred in ALK-positive non-small cell lung cancer and is important in managing locally advanced and metastatic NSCLC. It is important for the reader to understand its role and action.	
Is the title of the article suitable? (If not, please suggest an alternative title)	Yes	
Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here.	Yes	
Are subsections and structure of the manuscript appropriate?	Yes	
Please write a few sentences regarding the scientific correctness of this manuscript. Why do you think that this manuscript is scientifically robust and technically sound? A minimum of 3-4 sentences may be required for this part.	This study mainly talks about the pharmacological perspective of the drug. This is important for the reader to understand about the drug and its adverse effects including clinical outcomes. Hence, it would be a good guide for the reader to understand the pharmacology behind the drug.	
Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form. -	Yes	
Minor REVISION comments		
Is the language/English quality of the article suitable for scholarly communications?	Yes	
Optional/General comments	<ol style="list-style-type: none"> It would be great if the authors could discuss the survival outcomes separately (tabulation need to be clearer). Kindly change the subheading of the manuscript to "Place in therapy". That way it would be more informative for the readers. Abbreviations in tabulation "ORR", "IORR", "PFS" need to be defined at the end of the table. 	

ReviewForm3

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with the reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, kindly please write down the ethical issues here in detail)</i> No	

Reviewer Details:

Name:	Arjun Pon Avudaiappan
Department, University & Country	Miami Cancer Institute, United States